Get the Stockscreener App
1.03
1.90%
-0.02
Biovie Inc stock is traded at $1.03, with a volume of 508.87K.
It is down -1.90% in the last 24 hours and up +29.85% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.05
Open:
$1.03
24h Volume:
508.87K
Relative Volume:
1.18
Market Cap:
$19.12M
Revenue:
-
Net Income/Loss:
$-25.56M
P/E Ratio:
-0.1981
EPS:
-5.2
Net Cash Flow:
$-19.35M
1W Performance:
-8.04%
1M Performance:
+29.85%
6M Performance:
-67.71%
1Y Performance:
-79.35%
1-Day Range:
$1.0201
$1.10
1-Week Range:
$1.00
$1.20
52-Week Range:
$0.62
$7.50
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.03 | 20.67M | 0 | -25.56M | -19.35M | -5.20 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - voiceofalexandria.com
BioVie Inc. Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - marketscreener.com
BioVie (BIVI) Begins Phase 2 Trial for Long COVID Treatment | BI - GuruFocus
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial - GlobeNewswire
New Long COVID Treatment Hope: BioVie Launches Phase 2 Trial for 20M+ US Patients with Brain Fog - Stock Titan
BioVie (BIVI) To Host Key Opinion Leader Event Discussing Parkin - GuruFocus
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of - GuruFocus
BioVie to host KOL event on Phase 2 study of bezisterim - TipRanks
BioVie to Host Virtual KOL Event to Discuss the Phase 2 - GlobeNewswire
Biovie Inc. to Host Virtual Kol Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 - marketscreener.com
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
BIOVIE Earnings Results: $BIVI Reports Quarterly Earnings - Nasdaq
BIOVIE INC. SEC 10-Q Report - TradingView
Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
BioVie (BIVI) to Release Quarterly Earnings on Tuesday - Defense World
Investors who lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
BioVie Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsBIVI - ACCESS Newswire
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
Investors who lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024BIVI - ACCESS Newswire
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out - ACCESS Newswire
BioVie to Present Rationale and Design of Phase 2 - GlobeNewswire
BioVie (BIVI) Showcases Parkinson's Trial at Global Conference | BIVI Stock News - GuruFocus
Market Insights: BioVie Inc (BIVI)’s Notable Gain of 1.75, Closing at 1.16 - DWinneX
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025) - Stock Titan
BioVie (BIVI) Establishes Influential Corporate Advisory Board | - GuruFocus
BioVie assembles advisory board for neurodegenerative care By Investing.com - Investing.com Canada
BioVie (BIVI) Establishes Influential Corporate Advisory Board | BIVI Stock News - GuruFocus
BioVie assembles advisory board for neurodegenerative care - Investing.com
BioVie (BIVI) Advances Parkinson's Trial with Innovative Drug Be - GuruFocus
BioVie (BIVI) Advances Key Drug Treatments and Clinical Trials - GuruFocus
BioVie Unveils Corporate Advisory Board Featuring Neuralink - GlobeNewswire
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth - marketscreener.com
BioVie Inc. Announces Formation of Corporate Advisory Board - marketscreener.com
BioVie (BIVI) Advances Parkinson's Trial with Innovative Drug Bezisterim - GuruFocus
Geode Capital Management LLC Buys 85,234 Shares of BioVie Inc. (NASDAQ:BIVI) - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BioVie Inc (BIVI) Stock: A Year of Highs and Lows - investchronicle.com
Shareholders That Lost Money on BioVie Inc.(BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI) - The Wall Street Transcript
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioVie Inc.(BIVI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), a - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bank of Montreal Can Invests $100,000 in BioVie Inc. (NASDAQ:BIVI) - Defense World
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):